Press Release FeedGet the RSS feed
Menu

Search press releases

Every release here is real and links to its original. Filter by company, topic, language and date.

2,076 resultsPage 16 of 173, newest first
  1. SaaSGlobal TimesGlobal Times: Three times in the People's Daily: How the BRI has shaped an Egyptian life over 14 yearsIn early September 2026, Egyptian young man named Abbas launched an account on a Chinese social media platform. In his profile, he proudly noted that he had been featured three times in the People's Daily. His first post was the newspaper's latest...
  2. AITwo Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA PlatformHong Kong, Oct 9, 2026 - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies. The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they will drive clinical development of the Company’s mRNA programs and expand Everest’s presence in the United States, in line with the Company’s global mRNA R&D strategy, while working closely with the China R&D team. The two scientists previously held leadership roles at Moderna, where they contributed to its mRNA cancer vaccine programs, including mRNA-4157/V940. Their experience spanning early-stage research through clinical development will support the advancement of Everest's proprietary mRNA platform and global clinical development programs. In August 2026, Moderna and Merck announced that mRNA-4157/V940 in combination with Keytruda met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 study. The results represent the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy. “We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest Medicines as we continue to strengthen our global mRNA R&D capabilities,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy.” Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept. Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics, which was later acquired by BioNTech, and Sanofi Oncology. Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020) and Cancer Cell (2022), and co-authored publications on Moderna’s intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024) and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026). Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies. Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), which reported positive results from the Phase 3 INTerpath-001 study in August 2026, becoming the first personalized neoantigen therapy and mRNA cancer therapy to achieve success in a Phase 3 clinical study. Dr. Coder also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106. He contributed to nine IND submissions as a co-inventor, research lead, or core contributor, and co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024). Prior to joining Moderna, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines. Leveraging its proprietary AI+mRNA platform, Everest Medicines is advancing multiple mRNA oncology therapeutic vaccine and in vivo CAR-T programs for oncology and autoimmune diseases. EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, EVM16 plans to initiate an investigator-initiated trial (IIT) Phase 1b study in Q4 2026 and launch new indication expansion cohorts for efficacy exploration. The company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027. EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China’s National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.EVM18, an in vivo CAR-T therapy, has initiated an IIT study in autoimmune diseases, with global IND filing underway. EVM15, an off-the-shelf immunomodulatory (IM) cancer vaccine, achieved clinical proof of concept in preclinical studies in 2025, with a clinical candidate subsequently selected. The Company plans to advance preparations for the Investigational New Drug (IND) application for EVM15 in 2026.
  3. FinanceFullerton and SGX Group open second Value-Up Singapore Equities Challenge to the public with new Open CategorySINGAPORE, Oct 9, 2026 - Fullerton Fund Management (“Fullerton”) and SGX Group, in partnership with Moomoo Singapore as Supporting Partner, launched the second edition of the Fullerton / SGX Value-Up Singapore Equities Challenge(1) (“The Challenge”) to the public for the first time, inviting Singaporeans and Permanent Residents aged 18 and above to test their investing skills on Singapore-listed small and mid-cap companies over eight weeks, with cash prizes for the top performers. The inaugural Challenge in 2025 was open to students only. This year’s edition adds an Open Category for the public while retaining the Student Category. Participants in both categories will research and manage virtual portfolios of eligible Singapore-listed securities, with a focus on Singapore’s small- and mid-cap (“SMID”) segment. The trading simulation does not involve real capital. The Challenge comes as interest in Singapore’s SMID segment grows. As of 30 June 2026, institutional net buying in SMID stocks had tripled year on year to S$606 million, while daily trading value rose 155% to S$310 million, its highest level since FY2014(2). The Challenge gives participants a structured and practical way to learn more about companies beyond the Straits Times Index. Open Category Open to Singapore Citizens and Permanent Residents aged 18 and above, the Open Category will run from 7 December 2026 to 29 January 2027 over an eight-week online trading period. Participants compete individually, constructing and managing portfolios from an eligible list of Singapore-listed securities. They will be ranked in real time on a leaderboard based on total portfolio return, with cash prizes of S$3,000, S$2,000 and S$1,000 for the top three participants. Student Category The Student Category returns for its second year and is open to Singapore Citizens and Permanent Residents aged 18 and above who are enrolled full-time in polytechnics or universities. Participants compete in teams of four in the same eight-week simulation, using eligible Singapore-listed securities focused primarily on the SMID segment. The top six teams from the qualifying round will advance to an in-person stock-pitch final, where they will present their research and investment thesis to a judging panel. The top three teams will receive cash prizes of S$10,000, S$5,000 and S$3,000. The category is designed to connect classroom learning with practical exposure to investing, industry practitioners and potential 8-month internship opportunities, through the Fullerton Singapore Value-Up Internship Programme. Building disciplined investment habits The Challenge is designed to encourage disciplined portfolio construction rather than concentrated bets. Participants must establish positions within the first five trading days. From 14 December 2026, portfolios must maintain at least 80% exposure to eligible securities at the end of each trading day, with cash holdings capped at 20%. When initiating or adding to a position, exposure to any individual eligible security must not exceed 10% of the portfolio’s total value. Each portfolio may hold no more than 30 eligible securities; leverage, margin and derivatives are not permitted. Through the Challenge, participants will be able to: Gain first-hand experience in researching and evaluating Singapore-listed companies. Develop practical habits around portfolio construction, risk management and investment decision-making. Build a stronger understanding of opportunities available within Singapore’s equities market beyond the benchmark index. Ken Goh, Chief Investment Officer, Fullerton Fund Management, said: “Over the past year, we have seen growing interest in Singapore equities, reflecting broader recognition of the depth and diversity of our domestic market. The objective of the Fullerton/SGX Value-Up Singapore Equities Challenge is to motivate participants to identify and capture rising shareholder value, by encouraging young investors and members of the public to research companies, assess their potential and construct portfolios with greater discipline. The Challenge also supports our broader commitment to talent development. Participants from the inaugural Challenge have since joined Fullerton as interns, demonstrating how practical exposure can help inspire and nurture the next generation of investment professionals. Through this Challenge, we hope to contribute to a more informed and engaged Singapore equities market, with a broader base of investors participating in its long-term development.” Ng Yao Loong, Head of Global Financial Markets, SGX Group, said: “In every market, there is a difference between what is well known and what is well understood. The Fullerton/SGX Value-Up Singapore Equities Challenge encourages participants to close that gap by researching the SMID segment, testing their assumptions and forming their own investment perspectives. By opening the Challenge to the public, we hope more people will discover the breadth of the Singapore stock market and deepen their understanding of the businesses behind it.” Jeyson Ng, CEO, Moomoo Singapore said: “We are pleased to support Fullerton and SGX, both of whom are Moomoo’s long-term strategic partners in the Singapore ecosystem, in making investing education more accessible to students and the wider public. Through practical learning resources on Singapore equities, company research and portfolio construction within the Moomoo app, we hope to help participants build the confidence and foundational skills to better understand the market. The Challenge also provides a meaningful platform for us to engage aspiring talent and nurture the next generation of finance and technology professionals.” Registration for both categories is open until 30 November 2026. A participant may register for either the Student Category or the Open Category (provided that it meets the relevant eligibility requirements), but not both. Interested parties may sign up at https://value-up.investsg.asia/ (1) Jointly developed by SGX Group and AlphaInvest (2) SGX Group Research About Fullerton Fund Management Fullerton Fund Management Company Ltd (“Fullerton”) is an active investment specialist, focused on optimising investment outcomes and enhancing investor experience. We help clients, including government entities, sovereign wealth funds, pension plans, insurance companies, private wealth and retail, from the region and beyond, to achieve their investment objectives through our suite of solutions. Our expertise encompasses equities, fixed income, multi-asset, alternatives and treasury management, across public and private markets. As an active manager, we place strong emphasis on performance, risk management and investment insights. Incorporated in 2003, Fullerton is headquartered in Singapore, and has associated offices in Shanghai, Brunei and Jakarta. Fullerton is part of a multi-asset management group, Seviora, a holding company established by Temasek. Income Insurance, one of Singapore’s leading insurers, is a minority shareholder of Fullerton. For more information, please visit www.fullertonfund.com About SGX Group (Singapore Exchange) SGX Group is one of the world’s most trusted international marketplaces, known for its stability and openness. Anchored in Singapore, we enable price discovery, capital formation and risk management across asset classes, supported by resilient infrastructure and robust clearing. We convene issuers, investors and intermediaries to create and grow markets that stand the test of time. Find out more at www.sgxgroup.com. About Moomoo Singapore Moomoo Singapore is a holistic wealth-tech platform building an intelligent investing ecosystem across its digital platform, physical experience stores and investor education community. Through the moomoo app, it provides everyday investors and professional clients with access to global markets, diverse investment products, advanced trading tools and AI-powered insights. Since launching in March 2021, Moomoo Singapore has evolved beyond an investing platform into a popular financial literacy resource and full-spectrum wealth platform, supporting investors from their first trade to managing sophisticated portfolios. It surpassed two million users in Singapore in June 2026, spanning retail investors to private wealth and institutional clients. Moomoo Financial Singapore Pte. Ltd. is a subsidiary of Nasdaq-listed Futu Holdings Limited (Nasdaq: FUTU). The firm is regulated by the Monetary Authority of Singapore and holds a Capital Markets Services Licence (CMS101000) and Major Payment Institution Licence (PS20200617). It also has exempt financial adviser status and is authorised to provide Digital Payment Token services. Moomoo Trustee (Singapore) Pte. Ltd. is a licensed trust company, while Moomoo Singapore is a DP Clearing Member, SGX-ST Trading Member, and SGX-DT Trading and Clearing Member of Singapore Exchange. Find out more at https://www.moomoo.com/sg For media queries, please contact: Rishika Tiwariemail: [email protected]
  4. AITwo Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA PlatformHong Kong, Oct 9, 2026 - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies. The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they will drive clinical development of the Company’s mRNA programs and expand Everest’s presence in the United States, in line with the Company’s global mRNA R&D strategy, while working closely with the China R&D team. The two scientists previously held leadership roles at Moderna, where they contributed to its mRNA cancer vaccine programs, including mRNA-4157/V940. Their experience spanning early-stage research through clinical development will support the advancement of Everest's proprietary mRNA platform and global clinical development programs. In August 2026, Moderna and Merck announced that mRNA-4157/V940 in combination with Keytruda met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 study. The results represent the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy. “We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest Medicines as we continue to strengthen our global mRNA R&D capabilities,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy.” Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept. Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics, which was later acquired by BioNTech, and Sanofi Oncology. Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020) and Cancer Cell (2022), and co-authored publications on Moderna’s intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024) and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026). Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies. Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), which reported positive results from the Phase 3 INTerpath-001 study in August 2026, becoming the first personalized neoantigen therapy and mRNA cancer therapy to achieve success in a Phase 3 clinical study. Dr. Coder also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106. He contributed to nine IND submissions as a co-inventor, research lead, or core contributor, and co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024). Prior to joining Moderna, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines. Leveraging its proprietary AI+mRNA platform, Everest Medicines is advancing multiple mRNA oncology therapeutic vaccine and in vivo CAR-T programs for oncology and autoimmune diseases. EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, EVM16 plans to initiate an investigator-initiated trial (IIT) Phase 1b study in Q4 2026 and launch new indication expansion cohorts for efficacy exploration. The company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027. EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China’s National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.EVM18, an in vivo CAR-T therapy, has initiated an IIT study in autoimmune diseases, with global IND filing underway. EVM15, an off-the-shelf immunomodulatory (IM) cancer vaccine, achieved clinical proof of concept in preclinical studies in 2025, with a clinical candidate subsequently selected. The Company plans to advance preparations for the Investigational New Drug (IND) application for EVM15 in 2026.
  5. SaaSNew Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in BaliUnder the Patronage of His Excellency Prabowo Subianto, President of the Republic of Indonesia — A new global platform for investment, capital formation and economic partnership will launch 3-4 December in Bali, Indonesia. The New Asia Forum...
  6. FinanceQuantisimo Corp., the Pure-Play Sovereign Quantum Vertical Platform “Root to Qubit” Formed by WISeQey and SEALSQ, Signs Definitive Business Combination Agreement with GigCapital8 Corp. to Become a Nasdaq-Listed Public CompanyQuantisimo Corp., the Pure-Play Sovereign Quantum Vertical Platform “Root to Qubit” Formed by WISeQey and SEALSQ, Signs Definitive Business Combination Agreement with GigCapital8 Corp. to Become a Nasdaq-Listed Public Company
  7. AISAP推動「自主營運企業」落地應用Companies: SAP香港, 2026年10月9日 - SAP在近日舉行的 SAP Connect 大會展示「自主營運企業」（Autonomous Enterprise）的實際應用，演示 Joule Work 與智能助手 Joule Assistants 如何為各業務範疇的客戶創造價值。 SAP 全球行政總裁柯睿安（Christian Klein）表示：「這是企業級業務人工智能（Business AI）的突破性時刻，自主營運企業的應用正在加速落地。透過基於 SAP Business AI 平台構建的 Joule 及 SAP Autonomous Suite，我們正協助諾華（Novartis）、Morgan Foods、雀巢（Nestlé）及普華永道（PwC）等機構，在不同職能範疇推動智能化應用，並交付值得信賴的業務成果。」 在 SAP Connect 上，客戶們分享了Autonomous Enterprise正如何為其業務帶來可量化的價值： - 諾華採購負責人 Christoph Buerki表示：「我們與SAP共同研發的Joule Sourcing Assistant於近期已推出先導項目，其願景是讓AI Agent承接處理繁重且重複的工作，讓採購專業人員能夠專注於制定策略、與供應商協作及創造價值。」 - Morgan Foods首席財務官Steve Hankins表示：「我們已經著手為Agent應用做好準備，尤其是在技術基礎層面。最大的轉變將是從被動響應轉向預測性管理，Agent能夠比以往更快地連接需求信號、庫存水平及供應商狀態。我們的『超能力』來自人與Agent的協同。我們約 1,000 名員工是供應鏈運轉的根本，技術則讓他們發揮得更好。」 - 雀巢全球IT創新與企業架構負責人Luca Dell'Orletta表示：「我們在 140 個國家推進 SAP S/4HANA 轉型，正在構建一個互聯的數字核心，透過統一的流程、可信的數據以及跨市場和業務職能的更高可視性，為企業奠定堅實基礎。在此基礎上，Joule 與Accounts Receivable Assistant能夠根據風險和業務背景自動確定催收工作的優先等級，推薦下一步最佳行動，並協助財務團隊更快應對變化。」 - 普華永道首席會計官、財務總監及業務服務負責人Jill Notz表示：「在專業服務領域，賬單開發可能是最容易出錯的流程之一，而準確性對於客戶體驗至關重要。SAP Billing Assistant為這一關鍵流程注入更強的智能，協助更早識別潛在問題，幫助員工為客戶帶來更好的成果，並建立更牢固的客戶關係。在 Billing Assistant 取得成功的基礎上，普華永道與 SAP 正進一步拓展合作，在更多領域開展聯合 AI 創新。」 SAP 推動「自主營運企業」規模化發展 Joule Work 開始面向客戶推出，作為全新的 AI 用戶交互界面，讓員工能夠使用自然語言與 SAP 解決方案進行交互，並跨 SAP 及第三方數據完成工作。 依托 SAP Knowledge Graph 提供的業務語義上下文，該知識圖譜涵蓋逾 700 萬個數據字段，Joule 可以為用戶提供可靠的信息。 在 SAP 內部，Joule Work 已經服務於 11 萬名員工，公司在財務、人力資源及採購等領域實現 20% 的生產力提升。部分客戶也已在其業務環境中使用 Joule Work。 Maschinenfabrik Reinhausen複雜性管理總監 Peter Wied表示：「作為 SAP 客戶已有 28 年，我們與 SAP 在 AI 轉型之旅及 Joule Work Desktop 早期採用計劃上的合作，短短幾個月內取得的推進速度和勢頭，遠超我們過去多年的經驗。過去，在 SAP S/4HANA 環境中完成一些工作可能需要長達一小時的手動操作；如今，通過慣用語言，只需幾秒鐘即可完成。這從根本上改變了我們的團隊與業務數據交互的方式。」 CONA Services的SAP 平台架構師Keith Smith表示：「SAP 專屬團隊表現非常出色。他們積極主動地溝通，專注於加速架構啟用，快速解決缺陷，並提供全面支援，使我們能夠比在沒有他們幫助的情況下自行應對這些挑戰，更早做好 Joule 的準備。CONA 團隊對目前取得的進展感到振奮，並期待在未來幾個月繼續推進採用，同時進一步探索和測試 Joule 的各項能力。」 當單純查詢不足以滿足客戶需求時，Joule Assistants可以直接在業務工作流中執行營運任務，並利用既有的數據、授權機制和審計軌跡。客戶可以自主控制 AI 的自動化程度。SAP 的方法同樣強調開放性：透過 Agent2Agent 協議，Joule 可以與第三方 AI 和Agent連接，將受管理的業務語義上下文引入更廣泛的 AI 工作流。 在 SAP Connect 大會上，SAP 展示了這些能力如何透過 SAP Autonomous Suite在不同業務領域創造實際成果： - 財務領域：財務管理人員可自動化收入確認、信息披露及貿易合規等流程；International Trade Assistant的早期部署已將貿易分類工作減少多達 50%。 - 供應鏈領域：計劃人員可以將原本需要數小時處理的供應鏈中斷問題，轉化為跨計劃、製造和物流的一鍵解決。 - 人力資源領域：領導者可確定填補人力缺口的更佳做式，員工也可根據自身需要作出更明智的福利選擇。 - 採購領域：決策者可以透過與內置行業基準進行比較，識別節省成本的機會，並管理整個外部勞動力生命週期。 - 客戶體驗領域：企業可借助 AI 驅動的營銷活動、報價與客戶工作流程，將客戶互動轉化為銷售機會。 - 行業應用：SAP 正與不同客戶合作，將 AI 應用於專業化的行業業務流程，幫助製造、零售、大宗商品交易及資產密集型行業的企業改善決策、自動執行常規任務，並構建更具韌性的營運體系。 打造可信的商業AI平台 SAP Business AI 平台為企業提供統一的 AI 能力賦能平台，用於在 SAP 及第三方環境中構建、賦予業務語義情境並管理 AI。借助 Joule Studio，業務用戶與開發人員可透過無代碼到專業代碼工作流程，構建與擴展技能及Agent，並可從 70 多個 AI 模型中進行選擇。SAP Business Data Cloud與 SAP Knowledge Graph 為這些Agent提供可信的業務數據和情境支撐，幫助企業為每個使用場景選擇合適的模型，並更好地管理 AI 價值和使用情況。 SAP 提供的管理能力幫助企業以透明、負責任且可控的方式規模化部署 AI。 SAP LeanIX 解決方案中的 SAP AI Agent Hub 提供企業Agent的集中化清單管理，而 SAP 獨立通過 ISO/IEC 42001 認證的管理架構，則支援合規要求、既定授權和可審核的 AI 運營。 為了幫助企業實現 AI 的規模化採用，SAP 的Business Transformation Management產品組合，包括 SAP Signavio、SAP LeanIX 及 SAP WalkMe 解決方案，提供完整工具鏈，用於分析業務流程、管理應用和Agent，並推動整個企業範圍內的採用。 SAP將嵌入式支付引入Cloud ERP SAP 同時宣布正式進入支付市場，推出由 SAP 旗下公司 Tereina 提供支持的 SAP Pay。 SAP Pay 直接嵌入 SAP Cloud ERP。當帳單到期時，SAP Pay 可以在同一業務工作流中執行並完成支付對賬，從而減少人工文件處理和對外部處理流程的依賴，同時為客戶提供更強的控制能力。 合作夥伴拓展自主業務的應用範圍 SAP 正通過一系列新的合作夥伴關係，將自主營運企業能力拓展至 SAP 自身應用組合之外，把專業化智能能力直接帶入 SAP 工作流程。 SAP與穆迪（Moody's Corporation）的新合作旨在將穆迪的供應商風險監控數據嵌入 SAP Ariba Supplier Lifecycle and Performance。 這讓採購團隊能夠在決策時持續獲取有關供應商財務健康狀況、營運風險和合規狀態的持續更新洞察。 企業將能夠從定期風險審查轉向持續監控，使 Joule Agent能夠在中斷影響業務之前預警供應商風險信號，並提供替代方案。 與ORO Labs的擴展合作，將採購編排能力作為解決方案擴展帶給 SAP 客戶。 由 ORO Labs 提供的 SAP Ariba Procurement Orchestration解決方案是專門打造的採購編排層，能夠在異構企業環境中端到端連接採購工作流，為業務用戶在需求提交、任務執行和全流程可視化方面提供無縫體驗。 更多內容請參閱：《2026 Connect 創新新聞指南》
  8. FinanceFrom Phase III Trials to Commercialization Partnerships, MindRank's AI Drug Development Value Comes into FocusHong Kong, Oct 9, 2026 - As AI Drug Development Approaches Commercialization, MindRank Marks a Key Business Milestone How much value can AI create in the discovery and development of new medicines' For investors following the sector, the answer lies in tangible progress in drug development and business execution. A platform’s ability to consistently generate drug candidates, advance lead assets through clinical development and secure recognition from industry partners provides an important basis for assessing an AI drug developer’s growth potential. The recently announced commercialization partnership by MindRank AI Ltd. (MindRank, hereinafter “MindRank”) offers a new window into this question. On September 28, 2026, MindRank announced an exclusive commercialization partnership with 3SBio (01530.HK) subsidiaries Sunshine Mandi and Wansheng Pharmaceutical for MDR-001, its internally developed, AI-designed oral small-molecule GLP-1 receptor agonist. Covering mainland China, Hong Kong and Macau, the agreement carries a potential total transaction value of up to RMB1.75 billion, alongside a substantial share of sales revenue. MDR-001 is currently undergoing a pivotal Phase III clinical trial in China in adults with obesity or overweight. For MindRank, a clinical-stage AI-native drug discovery and development technology company, the partnership further connects drug development with commercialization planning. It lays the groundwork for marketing its lead asset following potential approval and establishes a clearer pathway for translating AI-driven research into commercial value. As its lead asset advances through pivotal clinical development, MindRank has begun preparing for post-approval marketing and channel coverage, extending the product’s development pathway into commercialization. Under the agreement, Sunshine Mandi and Wansheng Pharmaceutical will provide exclusive, comprehensive services and distribution across all channels following MDR-001’s launch. MindRank will retain all rights, title and interests in the product’s intellectual property and remain responsible for clinical development, regulatory submissions, manufacturing and supply. The transaction includes up to RMB150 million in payments for collaboration rights, up to RMB1.6 billion in royalty payments upon the fulfillment of agreed conditions, and a substantial share of sales revenue. From a business-model perspective, the agreement establishes a clear division of responsibilities. MindRank will continue investing in research and product development, while its partners will provide exclusive, comprehensive services and distribution across all channels within the agreed territories following regulatory approval and launch. In an industry that requires sustained investment, this collaboration could help MindRank retain its core asset rights while drawing on its partners’ commercial capabilities to support launch preparations and focus its own resources on strengthening its core capabilities. The partners’ willingness to make commercialization arrangements for an investigational drug also provides a new reference point for assessing its potential industry value. Clinical data address whether a product merits further development, while commercial partnerships indicate whether industry participants are willing to take part in its subsequent development. Together, these elements make MindRank’s growth story more tangible. A Lead Asset in Phase III Provides a Clearer Basis for Assessing AI-Driven R&D Capabilities The core asset underpinning the partnership is MDR-001, which continues to advance through development. In February 2026, MindRank announced that the first participant had been dosed in MOBILE, its Phase III clinical trial of MDR-001. According to the company, the multicenter, randomized, double-blind, placebo-controlled study plans to enroll approximately 750 participants across around 50 clinical centers in China to further evaluate the product’s long-term efficacy and safety. This means the evidence available to assess MindRank’s AI-driven R&D capabilities now extends to larger-scale, late-stage clinical research. For investors, the lead asset’s entry into Phase III sharpens the focus on several key questions: whether long-term efficacy can be further validated, whether safety and tolerability findings can be sustained, and whether the product can establish clinically meaningful competitive advantages. Previously disclosed Phase IIb findings supported further development. In the study, which enrolled 317 adults with obesity or overweight, participants in the MDR-001 dose groups achieved mean reductions in body weight from baseline of 8.2% to 10.3% after 24 weeks, compared with 2.5% in the placebo group. The rate of treatment discontinuation due to treatment-emergent adverse events was 0.8%. Common adverse events were primarily gastrointestinal and mostly mild to moderate. These findings remain subject to further validation in subsequent studies. For weight-management medicines, product value depends on a combination of weight-loss efficacy, long-term safety, tolerability and ease of use. Compared with the injectable peptide-based GLP-1 medicines that currently dominate the market, MDR-001’s oral small-molecule formulation can significantly improve medication adherence, while its large-scale manufacturing costs are substantially lower than those of peptide-based medicines, offering considerable market potential and commercial value. These attributes provide a promising direction for its future product positioning, although translating them into a competitive advantage will require continued accumulation of clinical evidence. Beyond progress in product development, R&D efficiency is another important lens through which to assess MindRank. According to the company, MDR-001 progressed from project initiation to preclinical candidate (PCC) nomination in just eight months, during which approximately 80 small molecules were synthesized. Its investigational new drug (IND) application was cleared in the United States within 19 months of project initiation and MDR-001 advanced to Phase III in China in approximately 4.5 years. In its July 2026 financing announcement, the company further disclosed that cumulative direct R&D investment in the program, from initiation through the start of Phase III in China, totaled approximately US$23 million. These timelines and investment figures provide a more concrete basis for understanding how MindRank organizes drug discovery and development. For drug developers, development timelines and funding requirements directly affect how many programs they can advance, how long they can sustain development and how they allocate resources to subsequent work. AI’s commercial significance must also be assessed within these real-world R&D constraints. As a flagship application of MindRank’s AI-driven drug discovery and development system, MDR-001 offers a traceable development pathway: from molecular design to clinical research and, subsequently, commercialization partnerships. The platform’s capabilities are beginning to be tested through tangible business outcomes. This provides capital markets with a more useful basis for understanding the company’s technology value than descriptions of algorithms or model parameters alone. Beyond the Lead Asset, Long-Term Growth Depends on Sustained Platform Output MDR-001 is the central focus of MindRank’s business progress at this stage, while the company’s long-term growth potential also depends on its ability to continue developing new drug assets. According to the MindRank, its end-to-end AI drug development engine, MAP (Molecule Arts Platform), integrates biology, chemistry, computation, experimental validation and clinical learning into a unified drug discovery and development system. In July 2026, the company announced that it had completed a cumulative US$52 million Series B financing in stages, with proceeds earmarked for further platform development and the advancement of its clinical and preclinical pipeline. In September 2026, the company formally launched Intera (Intelligence Era), its life-sciences foundation model system, and released a technical report on InteraFold-Chem, the first model in the InteraFold series. From an operating perspective, platform development and pipeline advancement have the potential to reinforce each other. R&D programs bring real-world problems and experimental feedback to the platform, while platform iterations support the discovery and optimization of subsequent programs. Ultimately, the platform’s value must be reflected in sustained output: its ability to advance more molecules with development potential across different targets and disease areas, gradually building a business supported by multiple assets. MindRank has already expanded beyond metabolic diseases. In March 2025, the company disclosed that MRANK-106, an oral dual inhibitor of WEE1 and YES1, had received IND approval in the U.S. in oncology. This development provides another case through which to assess the applicability of its AI platform across different R&D areas, although the product’s potential remains subject to subsequent clinical validation. In earlier-stage research, the company disclosed in April 2026 that a collaborative study on drug discovery for Alzheimer’s disease, conducted by MindRank, the University of Macau and Imperial College London, had been published in Nature Biomedical Engineering. The work combined AI screening with experimental validation to identify small molecules meriting further investigation, demonstrating the company’s research capabilities and exploration at the forefront of drug discovery for complex diseases. These programs are at different stages, and their contributions to the company’s value need to be assessed separately. MDR-001 remains the main focus of current clinical development and commercialization preparations, while other pipeline programs and research support the platform’s broader applicability and long-term project portfolio. As more programs deliver verifiable progress, outside observers will be better positioned to assess whether the company can consistently replicate its R&D capabilities. Viewed through this lens, the recent commercialization partnership offers an opportunity to reassess MindRank. Its lead asset has entered pivotal clinical development, partners are participating in commercialization preparations at an early stage, financing supports continued R&D, and its presence across multiple areas preserves opportunities for future growth. These interconnected developments make the company’s development trajectory easier for capital markets to understand. MDR-001 remains in clinical development and has not yet received marketing approval. Its future value realization depends on clinical results, regulatory approval and commercial execution. Nevertheless, the business progress achieved to date provides a more concrete basis for assessing MindRank. For investors following opportunities at the intersection of AI and innovative medicines, the central question worth tracking is whether the company can progressively translate its established R&D capabilities into more verifiable drug assets and commercial outcomes.
  9. AI從Ⅲ期臨床到商業化合作 德睿智藥的AI製藥價值逐步顯現香港, 2026年10月9日 - AI製藥進入準商業化階段，德睿智藥迎來關鍵業務進展 AI究竟能為新藥研發創造多大價值？對於關注這一領域的投資人而言，答案需要在具體的藥物和業務進展中尋找。研發平台能否持續產出候選藥物，核心產品能否取得臨床進展，以及研發成果能否獲得產業合作夥伴認可，共同構成了判斷一家AI製藥企業成長潛力的重要依據。 杭州德睿智藥科技有限公司（MindRank，以下簡稱「德睿智藥」）近期披露的商業化合作，為觀察這一問題提供了新的窗口。 2026年9月28日，德睿智藥宣布，與三生製藥（01530.HK）旗下三生蔓迪及萬晟醫藥，就其自主研發的AI設計口服小分子GLP-1受體激動劑MDR-001達成獨家商業化合作，覆蓋中國內地、香港及澳門，潛在總交易金額最高可達人民幣17.5億元，並可獲高比例銷售分成。該產品目前正在中國開展針對成人肥胖或超重人群的Ⅲ期關鍵臨床研究。 對於德睿智藥這家臨床階段AI Native新藥研發科技公司而言，此次合作進一步銜接了新藥研發與商業化布局，為核心產品未來獲批後的市場推廣奠定基礎，也讓AI驅動的研發成果向商業價值轉化的路徑更加清晰。在核心產品推進關鍵臨床研究的同時，德睿智藥開始為未來獲批後的市場推廣和渠道覆蓋作準備，使產品開發路徑進一步延伸至商業化環節。 根據協議安排，三生蔓迪及萬晟醫藥將承接MDR-001上市後的全渠道獨家綜合與經銷服務；德睿智藥保留產品知識產權的全部權利、權屬和權益，繼續負責臨床開發、註冊申報與生產供應。交易包括最高1.5億元合作權付款，以及達到約定條件後最高16億元的特許權使用付款，以及高比例銷售分成。 從業務模式來看，這一安排體現出明確的分工：德睿智藥持續投入研發及產品開發，合作方負責約定區域內、產品獲批上市後的全渠道獨家綜合與經銷服務。對於需要長期投入的創新藥業務，這種協同有望幫助德睿智藥在保留核心資產權益的同時，藉助合作方的商業運營能力銜接上市準備，並將自身資源集中於核心能力建設。 合作方願意圍繞一款在研產品作出商業化安排，也為外界評估其潛在產業價值提供了新的參考。臨床數據回答產品是否值得繼續開發，商業合作則進一步回答產業夥伴是否願意參與其後續發展。兩者相互銜接，使德睿智藥的成長邏輯更加具體。 核心產品邁入Ⅲ期，讓AI研發能力有了更清晰的觀察依據 支撐此次合作的核心資產，是持續取得研發進展的MDR-001。 2026年2月，德睿智藥宣布，MDR-001的Ⅲ期臨床研究MOBILE完成首例受試者給藥。根據公司披露，該研究採用多中心、隨機、雙盲、安慰劑對照設計，計劃在中國約50家臨床中心納入約750名受試者，進一步評價產品的長期有效性與安全性。 這意味著，評價德睿智藥AI研發能力的依據，已經延伸至較大規模的後期臨床研究。對於投資人而言，核心管線進入Ⅲ期，使後續觀察重點更加明確：長期療效能否得到進一步驗證，安全性和耐受性表現能否延續，以及產品能否形成具有實際臨床意義的競爭力。 此前披露的Ⅱb期研究為後續開發提供了支持。在這項納入317名成人肥胖或超重受試者的研究中，MDR-001各劑量組治療24周後平均體重較基線下降8.2%至10.3%，安慰劑組下降2.5%；因治療期間出現的不良事件而終止治療的比例為0.8%。研究中常見的不良事件主要為胃腸道症狀，多為輕至中度。上述結果仍需通過後續研究進一步驗證。 對於體重管理藥物，產品價值需要綜合考慮減重效果、長期安全性、耐受性和使用便利性。相較於當前主流的注射類多肽GLP-1藥物，MDR-001作為口服小分子製劑，可顯著提升患者用藥依從性，規模化製備成本遠低於多肽類藥物，將極具市場潛力和商業價值。這為其後續產品定位提供了一個值得關注的方向；而能否將這一特點轉化為實際競爭優勢，則需要持續積累臨床證據。 在產品進展之外，研發效率也是理解德睿智藥的重要角度。 據公司披露，MDR-001從項目啟動到確定臨床前候選化合物（PCC）僅用8個月，期間實際合成約80個小分子；從項目啟動至獲得美國新藥臨床試驗許可用時19個月，約4.5年推進至中國Ⅲ期臨床。公司2026年7月發布的融資消息進一步披露，從立項至中國Ⅲ期臨床啟動，項目累計直接研發投入約2,300萬美元。 這些時間與投入數據，為理解德睿智藥如何組織新藥研發提供了更具體的討論基礎。對於新藥研發企業而言，研發周期與資金投入直接關係到企業能夠推進多少項目、承擔多長時間的開發，以及如何安排後續資源。AI的商業意義，也需要放在這些真實的研發約束中衡量。 作為德睿智藥AI新藥研發體系的核心實踐，MDR-001已經提供了一條可追蹤的開發路徑：從分子設計到臨床研究，再到商業化合作，平台能力開始通過實際業務成果接受檢驗。這比單純介紹算法或模型參數，更有助於資本市場理解公司的技術價值。 從核心管線到平台延展，長期成長空間取決於持續產出能力 MDR-001決定了德睿智藥現階段最重要的業務看點，而公司的長期成長空間，還取決於能否持續開發出新的藥物資產。 德睿智藥披露的全鏈路AI製藥引擎MAP（Molecule Arts Platform），將生物學、化學、計算、實驗驗證與臨床學習納入統一新藥研發體系。2026年7月，公司宣布分階段完成累計5,200萬美元B輪融資，資金將用於繼續推進平台建設及臨床、臨床前管線開發。2026年9月，公司正式發布生命科學基座模型體系Intera (Intelligence Era)，並公布InteraFold系列首個模型InteraFold-Chem技術報告。 從經營角度看，平台建設與管線推進具有相互促進的潛力：研發項目為平台帶來真實問題和實驗反饋，平台迭代則服務於後續項目的發現與優化。其價值最終需要體現為持續產出能力——能否在不同靶點和疾病領域推進更多具備開發價值的分子，並逐步形成多項資產支撐的業務結構。 德睿智藥已在代謝疾病之外展開布局。公司於2025年3月披露，口服WEE1及YES1雙靶點抑制劑MRANK-106獲得美國FDA的新藥臨床試驗許可，擬用於開展腫瘤領域的臨床研究。這一進展為觀察其AI平台在不同研發方向上的適用性提供了另一個案例，相關產品潛力仍需後續臨床驗證。 在更早期的研究方面，公司於2026年4月披露，德睿智藥與澳門大學、帝國理工學院合作開展的阿爾茨海默病藥物發現研究發表於《Nature Biomedical Engineering》。相關工作將AI篩選與實驗驗證結合，發現具有進一步研究價值的小分子，體現了公司在複雜疾病藥物發現方向上的前沿探索和研發能力。 這些項目所處階段不同，對公司價值的貢獻也需要分別觀察：MDR-001承擔現階段臨床開發與商業化準備的主要看點，其他管線和研究則為平台的延展能力及長期項目儲備提供支持。隨著更多項目取得可驗證的進展，外界才能進一步判斷公司的研發能力能否穩定複製。 從這一視角看，近期商業化合作為重新認識德睿智藥提供了契機。核心產品進入關鍵臨床階段，合作夥伴提前參與商業化準備，融資為持續研發提供支持，多方向布局則保留了後續成長的可能性。幾項進展相互聯繫，使公司的發展路徑更容易被資本市場理解。 MDR-001目前仍處於臨床開發階段，尚未獲批上市，其後續價值實現取決於臨床結果、監管審批及商業執行。但已經取得的業務進展，使德睿智藥具備了更具體的觀察基礎。對於關注AI與創新藥交匯機會的投資人而言，公司值得持續跟蹤的核心，在於能否將已經形成的研發能力，逐步轉化為更多可驗證的藥物資產與商業成果。
  10. AI从Ⅲ期临床到商业化合作 德睿智药的AI制药价值逐步显现香港, 2026年10月9日 - (亚太商讯) - AI制药进入准商业化阶段，德睿智药迎来关键业务进展 AI究竟能为新药研发创造多大价值？对于关注这一领域的投资人而言，答案需要在具体的药物和业务进展中寻找。研发平台能否持续产出候选药物，核心产品能否取得临床进展，以及研发成果能否获得产业合作伙伴认可，共同构成了判断一家AI制药企业成长潜力的重要依据。 杭州德睿智药科技有限公司（MindRank，以下简称“德睿智药”）近期披露的商业化合作，为观察这一问题提供了新的窗口。 2026年9月28日，德睿智药宣布，与三生制药（01530.HK）旗下三生蔓迪及万晟医药，就其自主研发的AI设计口服小分子GLP-1受体激动剂MDR-001达成独家商业化合作，覆盖中国内地、香港及澳门，潜在总交易金额最高可达人民币17.5亿元，并可获高比例销售分成。该产品目前正在中国开展针对成人肥胖或超重人群的Ⅲ期关键临床研究。 对于德睿智药这家临床阶段AI Native新药研发科技公司而言，此次合作进一步衔接了新药研发与商业化布局，为核心产品未来获批后的市场推广奠定基础，也让AI驱动的研发成果向商业价值转化的路径更加清晰。在核心产品推进关键临床研究的同时，德睿智药开始为未来获批后的市场推广和渠道覆盖作准备，使产品开发路径进一步延伸至商业化环节。 根据协议安排，三生蔓迪及万晟医药将承接MDR-001上市后的全渠道独家综合与经销服务；德睿智药保留产品知识产权的全部权利、权属和权益，继续负责临床开发、注册申报与生产供应。交易包括最高1.5亿元合作权付款，以及达到约定条件后最高16亿元的特许权使用付款，以及高比例销售分成。 从业务模式来看，这一安排体现出明确的分工：德睿智药持续投入研发及产品开发，合作方负责约定区域内、产品获批上市后的全渠道独家综合与经销服务。对于需要长期投入的创新药业务，这种协同有望帮助德睿智药在保留核心资产权益的同时，借助合作方的商业运营能力衔接上市准备，并将自身资源集中于核心能力建设。 合作方愿意围绕一款在研产品作出商业化安排，也为外界评估其潜在产业价值提供了新的参考。临床数据回答产品是否值得继续开发，商业合作则进一步回答产业伙伴是否愿意参与其后续发展。两者相互衔接，使德睿智药的成长逻辑更加具体。 核心产品迈入Ⅲ期，让AI研发能力有了更清晰的观察依据 支撑此次合作的核心资产，是持续取得研发进展的MDR-001。 2026年2月，德睿智药宣布，MDR-001的Ⅲ期临床研究MOBILE完成首例受试者给药。根据公司披露，该研究采用多中心、随机、双盲、安慰剂对照设计，计划在中国约50家临床中心纳入约750名受试者，进一步评价产品的长期有效性与安全性。 这意味着，评价德睿智药AI研发能力的依据，已经延伸至较大规模的后期临床研究。对于投资人而言，核心管线进入Ⅲ期，使后续观察重点更加明确：长期疗效能否得到进一步验证，安全性和耐受性表现能否延续，以及产品能否形成具有实际临床意义的竞争力。 此前披露的Ⅱb期研究为后续开发提供了支持。在这项纳入317名成人肥胖或超重受试者的研究中，MDR-001各剂量组治疗24周后平均体重较基线下降8.2%至10.3%，安慰剂组下降2.5%；因治疗期间出现的不良事件而终止治疗的比例为0.8%。研究中常见的不良事件主要为胃肠道症状，多为轻至中度。上述结果仍需通过后续研究进一步验证。 对于体重管理药物，产品价值需要综合考虑减重效果、长期安全性、耐受性和使用便利性。相较于当前主流的注射类多肽GLP-1药物，MDR-001作为口服小分子制剂，可显著提升患者用药依从性，规模化制备成本远低于多肽类药物，将极具市场潜力和商业价值。这为其后续产品定位提供了一个值得关注的方向；而能否将这一特点转化为实际竞争优势，则需要持续积累临床证据。 在产品进展之外，研发效率也是理解德睿智药的重要角度。 据公司披露，MDR-001从项目启动到确定临床前候选化合物（PCC）仅用8个月，期间实际合成约80个小分子；从项目启动至获得美国新药临床试验许可用时19个月，约4.5年推进至中国Ⅲ期临床。公司2026年7月发布的融资消息进一步披露，从立项至中国Ⅲ期临床启动，项目累计直接研发投入约2,300万美元。 这些时间与投入数据，为理解德睿智药如何组织新药研发提供了更具体的讨论基础。对于新药研发企业而言，研发周期与资金投入直接关系到企业能够推进多少项目、承担多长时间的开发，以及如何安排后续资源。AI的商业意义，也需要放在这些真实的研发约束中衡量。 作为德睿智药AI新药研发体系的核心实践，MDR-001已经提供了一条可追踪的开发路径：从分子设计到临床研究，再到商业化合作，平台能力开始通过实际业务成果接受检验。这比单纯介绍算法或模型参数，更有助于资本市场理解公司的技术价值。 从核心管线到平台延展，长期成长空间取决于持续产出能力 MDR-001决定了德睿智药现阶段最重要的业务看点，而公司的长期成长空间，还取决于能否持续开发出新的药物资产。 德睿智药披露的全链路AI制药引擎MAP（Molecule Arts Platform），将生物学、化学、计算、实验验证与临床学习纳入统一新药研发体系。2026年7月，公司宣布分阶段完成累计5,200万美元B轮融资，资金将用于继续推进平台建设及临床、临床前管线开发。2026年9月，公司正式发布生命科学基座模型体系Intera (Intelligence Era)，并公布InteraFold系列首个模型InteraFold-Chem技术报告。 从经营角度看，平台建设与管线推进具有相互促进的潜力：研发项目为平台带来真实问题和实验反馈，平台迭代则服务于后续项目的发现与优化。其价值最终需要体现为持续产出能力——能否在不同靶点和疾病领域推进更多具备开发价值的分子，并逐步形成多项资产支撑的业务结构。 德睿智药已在代谢疾病之外展开布局。公司于2025年3月披露，口服WEE1及YES1双靶点抑制剂MRANK-106获得美国FDA的新药临床试验许可，拟用于开展肿瘤领域的临床研究。这一进展为观察其AI平台在不同研发方向上的适用性提供了另一个案例，相关产品潜力仍需后续临床验证。 在更早期的研究方面，公司于2026年4月披露，德睿智药与澳门大学、帝国理工学院合作开展的阿尔茨海默病药物发现研究发表于《Nature Biomedical Engineering》。相关工作将AI筛选与实验验证结合，发现具有进一步研究价值的小分子，体现了公司在复杂疾病药物发现方向上的前沿探索和研发能力。 这些项目所处阶段不同，对公司价值的贡献也需要分别观察：MDR-001承担现阶段临床开发与商业化准备的主要看点，其他管线和研究则为平台的延展能力及长期项目储备提供支持。随着更多项目取得可验证的进展，外界才能进一步判断公司的研发能力能否稳定复制。 从这一视角看，近期商业化合作为重新认识德睿智药提供了契机。核心产品进入关键临床阶段，合作伙伴提前参与商业化准备，融资为持续研发提供支持，多方向布局则保留了后续成长的可能性。几项进展相互联系，使公司的发展路径更容易被资本市场理解。 MDR-001目前仍处于临床开发阶段，尚未获批上市，其后续价值实现取决于临床结果、监管审批及商业执行。但已经取得的业务进展，使德睿智药具备了更具体的观察基础。对于关注AI与创新药交汇机会的投资人而言，公司值得持续跟踪的核心，在于能否将已经形成的研发能力，逐步转化为更多可验证的药物资产与商业成果。 Copyright 2026 亚太商讯. All rights reserved. www.acnnewswire.com
  11. AIBitdeer Technologies GroupBitdeer AI Expands Southeast Asia Footprint with A901, a New 67MW AI Data Center Campus in Malaysia; Active AI Cloud Pipeline Exceeds $10 Billion67MW expansion brings Bitdeer AI’s secured AI Cloud data center capacity to approximately 273.5MW, or approximately 78% of its target of up to 350MW to be delivered by the first quarter of 2028
  12. FinanceTNCDP Joins KoreInside Infrastructure to Advance Digital Preferred Stock Through Its Capital Markets PlatformTNCDP Joins KoreInside Infrastructure to Advance Digital Preferred Stock Through Its Capital Markets Platform